| Literature DB >> 30157944 |
Nouh Saad Mohamed1,2,3, Emmanuel Edwar Siddig4,5,6, Mona Ali Mohamed7, Basma AbdlMoniem Alzein6, Hanaa Hashim Saeed Osman8, Emmanuel E Tanyous9, Bahaeldin K Elamin10,11, Ali Mahmoud Mohammed Edris4,12.
Abstract
OBJECTIVES: Renal transplantation procedure markedly increased over the past few decades. The risk of harboring parasitic diseases may affect transplant recipients during life expectancy. We aimed in this study to determine the enteroparasitosis frequency among renal transplant recipients in Khartoum state, Sudan. A case-control hospital-based study performed between November 2012 and May 2013, on 300 renal transplant recipients attending Sudanese Kidney Association hospital in Khartoum state, Sudan, along with 300 normal healthy individuals matching the case in age and sex. Stool samples were collected for parasitological studies.Entities:
Keywords: Khartoum; Parasitic infections; Renal transplant; Sudan
Mesh:
Year: 2018 PMID: 30157944 PMCID: PMC6114479 DOI: 10.1186/s13104-018-3716-8
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Illustrate the intestinal parasites distribution across the study population
| Parasites detected | Transplant recipients | Healthy participants | Total | P value |
|---|---|---|---|---|
| Negative | 236 (78.7%) | 246 (82.0%) | 482 (80.3%) | NA |
|
| 24 (8.0%) | 21 (7.0%) | 45 (7.5%) | 0.756 |
|
| 21 (7.0%) | 18 (6.0%) | 39 (6.5%) | 0.740 |
|
| 5 (1.7%) | 2 (0.7%) | 7 (1.2%) | 0.450 |
|
| 9 (3.0%) | 10 (3.3%) | 19 (3.2%) | 1.000 |
|
| 1 (0.3%) | 1 (0.3%) | 2 (0.3%) | 1.000 |
|
| 1 (0.3%) | 0 | 1 (0.2%) | 1.000 |
|
| 2 (0.7%) | 2 (0.7%) | 4 (0.7%) | 1.000 |
|
| 1 (0.3%) | 0 | 1 (0.2%) | 1.000 |
| Total | 300 (50.0%) | 300 (50.0%) | 600 (100%) |
Fig. 1The frequency of intestinal parasitosis among the different regimens groups used for the treatment of the renal transplanted recipients
Frequency of intestinal parasites among the different regimens used with renal transplant recipients
| Treatment | E. H/D | E. C | C. P | G. L | E. V | H. N | A. L | S. S | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cyclosporine with Cortisone | 3 (27.3%) | 5 (45.5%) | 0 (0.0%) | 2 (18.2%) | 0 (0.0%) | 0 (0.0%) | 1 (9.1%) | 0 (0.0%) | 11 (17.2%) |
| Cyclosporine with Azathioprine | 11 (39.3%) | 5 (17.9%) | 3 (10.7%) | 6 (21.4%) | 1 (3.6%) | 1 (3.6%) | 0 (0.0%) | 1 (3.6%) | 28 (43.8%) |
| Tacrolimus combined with Mycophenolate mofetil | 8 (44.4%) | 10 (55.6%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 18 (28.1%) |
| Cyclosporine combined with Cortisone and Mycophenolate mofetil | 2 (28.6%) | 1 (14.3%) | 2 (28.6%) | 1 (14.3%) | 0 (0.0%) | 0 (0.0%) | 1 (14.3%) | 0 (0.0%) | 7 (10.9%) |
| Total | 24 (37.5%) | 21 (32.8%) | 5 (7.8%) | 9 (14.0%) | 1 (1.6%) | 1 (1.6%) | 2 (3.1%) | 1 (1.6%) | 64 (100%) |
E. H/D: Entamoeba histolytica/dispare, E. C: Entamoeba coli, C. P: Cryptosporidium parvum, G. L: Giardia lambelia, E. V: Enterobius vermicularis, H. N: Hymenolepis nana, A. L: Ascaris lumbricoides, S. S: Strongyloides stercoralis